FDA approved drugs:
(show all 7)
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Lupron Depot
18
49
|
LEUPROLIDE ACETATE |
TAP Pharmaceuticals/ Abbott Laboratories |
July 1997/ January 1996 |
Disease/s that Drug Treats:prostate cancer
Indications and Usage:
18
LUPRON DEPOT is a gonadotropin releasing hormone (GnRH) agonistindicated for: palliative treatment of advanced prostatic cancer. (1)
DrugBank Targets:
16
1. Gonadotropin-releasing hormone receptor
Mechanism of Action:
18
Target: GnRH
Action: agonist
FDA: Leuprolide acetate, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animalstudies indicate that following an initial stimulation, continuous administration of leuprolideacetate results in suppression of ovarian and testicular steroidogenesis. This effect was reversibleupon discontinuation of drug therapy.Administration of leuprolide acetate has resulted in inhibition of the growth of certain hormonedependent tumors (prostatic tumors in Noble and Dunning male rats and DMBA-inducedmammary tumors in female rats) as well as atrophy of the reproductive organs.
|
| 2 |
|
Unituxin
18
49
|
DINUTUXIMAB |
United Therapeutics |
March 2015 |
Disease/s that Drug Treats:pediatrics with high-risk neuroblastoma
Indications and Usage:
18
Unituxin is a GD2-binding monoclonal antibody indicated, incombination with granulocyte-macrophage colony-stimulating factor(GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for thetreatment of pediatric patients with high-risk neuroblastoma whoachieve at least a partial response to prior first-line multiagent,multimodality therapy. (1)
DrugBank Targets:
16
1. Ganglioside GD2
Mechanism of Action:
18
Target: GD2
Action: inducer of cell lysis through ADCC and CDC
FDA: Dinutuximab binds to the glycolipid GD2. This glycolipid is expressed on neuroblastoma cellsand on normal cells of neuroectodermal origin, including the central nervous system andperipheral nerves. Dinutuximab binds to cell surface GD2 and induces cell lysis of GD2-expressing cells through antibody-dependent cell-mediated cytotoxicity (ADCC) andcomplement-dependent cytotoxicity (CDC).
|
| 3 |
|
Azmacort
18
|
TRIAMCINOLONE ACETONIDE |
Rhone Poulenc Rorer |
November 1996 |
Disease/s that Drug Treats:asthma
Indications and Usage:
18
Azmacort Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy. Azmacort Inhalation Aerosol is also indicated for asthma patients who require systemic corticosteroid administration, where adding Azmacort may reduce or eliminate the need for the systemic corticosteroids. Azmacort Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm.
DrugBank Targets:
16
Glucocorticoid receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: The precise mechanism of the action of glucocorticoids in asthma is unknown. However, the inhaled route makes it possible to provide effective local anti-inflammatory activity with reduced systemic corticosteroid effects. Though highly effective for asthma, glucocorticoids do not affect asthma symptoms immediately. While improvement in asthma may occur as soon as one week after initiation of Azmacort Azmacort Azmacort Inhalation Aerosol therapy, maximum improvement may not be achieved for 2 weeks or longer.
|
| 4 |
|
Dulera
18
|
FORMOTEROL FUMARATE; MOMETASONE FUROATE |
Merck |
June 2010 |
Disease/s that Drug Treats:asthma
Indications and Usage:
18
DULERA combines an inhaled corticosteroid medicine, mometasone furoate (the same medicine found in ASMANEX TWISTHALER), and a long-acting beta2-agonist medicine (LABA), formoterol (the same medicine found in FORADIL® AEROLIZER®). * Inhaled corticosteroids help to decrease inflammation in the lungs. Inflammation in the lungs can lead to asthma symptoms. * LABA medicines are used in people with asthma. LABA medicines help the muscles around the airways in your lungs stay relaxed to prevent asthma symptoms, such as wheezing and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe. In severe cases, wheezing can stop your breathing and may lead to death if not treated right away. DULERA is used to control symptoms of asthma and prevent symptoms such as wheezing in people 12 years of age and older. DULERA should not be used as a rescue inhaler. Do not use DULERA unless your healthcare provider has taught you and you understand everything. Ask your healthcare provider or pharmacist if you have any questions. * Use DULERA exactly as prescribed. Do not use DULERA more often than prescribed. DULERA comes in 2 strengths. Your healthcare provider has prescribed the strength that is best for you. Note the differences between DULERA and your other inhaled medications, including the differences in prescribed use and physical appearance. * DULERA should be taken every day as 2 puffs in the morning and 2 puffs in the evening. * If you miss a dose of DULERA, skip your missed dose and take your next dose at your regular time. Do not take DULERA more often or use more puffs than you have been prescribed. * While you are using DULERA 2 times each day, do not use other medicines that contain a longacting beta2-agonist (LABA) for any reason. Ask your healthcare provider or pharmacist if any of your other medicines are LABA medicines. * If you take more DULERA than your healthcare provider has prescribed, get medical help right away if you have any unusual symptoms, such as problems breathing, palpitations, chest pain, increased heart rate, nervousness or shakiness. * Do not change or stop using DULERA or other asthma medicines used to control or treat your breathing problems unless told to do so by your healthcare provider. Your healthcare provider will change your medicines as needed. * DULERA does not relieve sudden asthma symptoms. Always have a rescue inhaler with you to treat sudden symptoms. Use your rescue inhaler if you have breathing problems between doses of DULERA. If you do not have a rescue inhaler, call your healthcare provider to have one prescribed for you. * Remove the cap from the mouthpiece of the actuator before using DULERA. * DO NOT remove the canister from the actuator because: o You may not receive the correct amount of medication. o The dose counter may not function properly. o Reinsertion may cause the dose counter to count down by 1 and may discharge a puff. * Rinse your mouth with water after each dose (2 puffs) of DULERA. This will help to lessen the chance of getting a yeast infection (thrush) in the mouth and throat. * Do not spray DULERA in your eyes. If you accidentally get DULERA in your eyes, rinse your eyes with water and if redness or irritation continues, call your healthcare provider. * Call your healthcare provider or get medical care right away if: o your breathing problems worsen with DULERA o you need to use your rescue inhaler more often than usual o your rescue inhaler does not work as well for you at relieving symptoms o you need to use 4 or more inhalations of your rescue inhaler for 2 or more days in a row o you use 1 whole canister of your rescue inhaler in 8 weeksâ time o your peak flow meter results decrease. Your healthcare provider will tell you the numbers that are right for you. o you have asthma and your symptoms do not improve after using DULERA regularly for 1 to 2 weeks
DrugBank Targets:
16
16
Beta-2 adrenergic receptor|Glucocorticoid receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 5 |
|
Kalydeco
18
|
IVACAFTOR |
Vertex Pharmaceuticals |
January of 2012 |
Disease/s that Drug Treats:cystic fibrosis with the G551D mutation in the CFTR gene
Indications and Usage:
18
KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. KALYDECO is indicated for the treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene. If the patientâs genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (1) Limitations of Use: * Not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene. (1, 14)
DrugBank Targets:
16
Cystic fibrosis transmembrane conductance regulator
Mechanism of Action:
18
Target: cystic fibrosis transmembrane conductance regulator (CFTR)
Action: potentiator
FDA: Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein. In vitro, ivacaftor increased CFTR-mediated transepithelial current (IT) in rodent cells expressing the G551D-CFTR protein following addition of a cyclic adenosine monophosphate (cAMP) agonist with an EC50 of 100 ± 47 nM; however, ivacaftor did not increase IT in the absence of cAMP agonist. Ivacaftor also increased IT in human bronchial epithelial cells expressing G551D-CFTR protein following addition of a cAMP agonist by 10-fold with an EC50 of 236 ± 200 nM. Ivacaftor increased the open probability of G551D-CFTR protein in single channel patch clamp experiments using membrane patches from rodent cells expressing G551D-CFTR protein by 6-fold versus untreated cells after addition of PKA and ATP. In addition to G551D-CFTR, ivacaftor increased the channel-open probability of other mutant CFTR forms expressed in rodent cells, resulting in enhanced CFTR-mediated IT. These mutant CFTR forms included G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-, S1251N-, S1255P-, and G1349D-CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has low channel-open probability (gating) and reduced channel current amplitude (conductance) compared to normal CFTR. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.
|
| 6 |
|
Tequin
18
|
|
Bristol-Myers Squibb |
December, 1999 |
Disease/s that Drug Treats:Community-acquired respiratory tract infections
Indications and Usage:
18
DrugBank Targets:
16
DNA gyrase subunit A|DNA gyrase subunit B|DNA topoisomerase 4 subunit A|DNA topoisomerase 4 subunit B
Mechanism of Action:
18
Target: DNA gyrase
Action: inhibitor
FDA: -
|
| 7 |
|
Vibativ
18
|
* TELAVANCIN * TELAVANCIN HYDROCHLORIDE |
Theravance |
June 2013 |
Disease/s that Drug Treats:hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus
Indications and Usage:
18
VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: * Complicated skin and skin structure infections (cSSSI) (1.1) * Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus. VIBATIV should be reserved for use when alternative treatments are not suitable. (1.2)
DrugBank Targets:
-
Mechanism of Action:
18
Target: late-stage peptidoglycan precursors
Action: inhibits cell wall biosynthesis
FDA: Telavancin is an antibacterial drug [see Clinical Pharmacology (12.4)]. Telavancin inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II. Telavancin also binds to the bacterial membrane and disrupts membrane barrier function.
|
Drugs for Lambert-Eaton Myasthenic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 23)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
4-Aminopyridine |
Approved |
Phase 3,Phase 2,Not Applicable |
|
504-24-5 |
1727
|
|
Synonyms:
.gamma.-Aminopyridine
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 Aminopyridine
4 Aminopyridine Sustained Release
4 AP
4-aminopyridine
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-AP
4-Pyridinamine
4-Pyridylamine
504-24-5
5-22-09-00106 (Beilstein Handbook Reference)
A 0152
A0414
A78403_ALDRICH
AB1004971
AC1L1C3R
AC1Q52BM
AC-907/25014071
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
BRN 0105782
BSPBio_001562
C13728
C5H6N2
Caswell No. 038
CHEBI:34385
CHEMBL284348
CID1727
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine [USAN:INN]
Fampridine SR
Fampridine-PR
Fampridine-SR
Fampridinum
FT-0083754
gamma-Aminopyridine
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
|
KBio1_000572
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
Lopac0_000032
Lopac-A-0152
LS-130202
Mi-W-3
MLS000069400
MolPort-000-146-022
N07XX07
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
nchem.892-comp4
Neurelan
Neurelan (TN)
NINDS_000572
NSC 15041
NSC15041
p-Aminopyridine
P-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
pyridin-4-amine
pyridin-4-ylamine
PYRIDINE,4-AMINO
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
Spectrum_000155
SPECTRUM1501130
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
STK298717
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 103
VMI 10-3
VMI103
VMI-103
VMI-10-3
WLN: T6NJ DZ
|
|
| 2 |
|
Pembrolizumab |
Approved |
Phase 3 |
|
1374853-91-4 |
|
|
Synonyms:
|
| 3 |
|
3,4-diaminopyridine |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 4 |
|
Potassium Channel Blockers |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 5 |
|
Pseudoephedrine |
Approved |
Phase 1, Phase 2 |
|
90-82-4 |
7028
|
|
Synonyms:
( )-Pseudoephedrine
(+) threo-2-(methylamino)-1-phenyl-1-propanol
(+) threo-2-(methylamino)-1-Phenyl-1-propanol
(+)-(1S,2S)-Pseudoephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-Psi-ephedrine
(+)-threo-Ephedrine
(1S,2S)-(+)-Pseudoephedrine
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
(1S,2S)-2-Methylamino-1-phenyl-1-propanol
(1S,2S)-Pseudoephedrine
(1S,2S)-Pseudoephedrine, polymer-bound
1-Ephedrine
2-(methylamino)-1-Phenyl-1-propanol
287636_ALDRICH
304-87-0
30987-59-8
37577-31-4
649031_ALDRICH
90-82-4
AC1L1NUA
AC-20292
Acunaso
Acunaso (TN)
Afrinol
alpha-(1-(Methylamino)ethyl)benzyl alcohol
Balminil Decongestant Syrup
Benylin Decongestant
Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI)
Besan
BIDD:GT0817
BRD-K84175871-003-02-2
BSPBio_003261
C02765
C10H15NO
Cenafed
CHEBI:51209
CHEMBL1590
CID7028
CPD-9954
D08449
DB00852
Decofed
Dimetapp Decongestant
Dimetapp Decongestant Pediatric Drops
d-Isoephedrine
D-Isoephedrine
DivK1c_000451
d-Pseudoephedrine
D-Pseudoephedrine
D-Pseudoephedrine base
d-psi-2-Methylamino-1-phenyl-1-propanol
D-Psi-2-methylamino-1-phenyl-1-propanol
d-psi-Ephedrine
D-Psi-ephedrine
Drixoral N.D.
Drixoral Nasal Decongestant
Efidac 24 Pseudoephedrine Hcl
Efidac/24
EINECS 202-018-6
Eltor 120
Ephedrine
Ephedrine threo isomer
Genaphed
HSDB 3177
|
I01-8928
IDI1_000451
Isoephedrine
KBio1_000451
KBio2_001358
KBio2_003926
KBio2_006494
KBio3_002762
KBioGR_001763
KBioSS_001358
L-(+)-Pseudoephedrine
L(+)-psi-Ephedrine
L(+)-Psi-ephedrine
Lopac-E-3250
LS-125922
Maxenal
MolPort-001-684-474
Myfedrine
NCGC00015408-01
NCGC00178180-01
NCI60_002955
Neodurasina
Neodurasina (TN)
NINDS_000451
Novafed
PDSP1_001347
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoefedrina [INN-Spanish]
PSEUDOEPHEDRINE
pseudoéphédrine
Pseudoephedrine (D)
Pseudoephedrine (INN)
Pseudoephedrine [INN:BAN]
Pseudoephedrine d-form
Pseudoephedrine D-form
Pseudoephedrine ephedrine
Pseudoephedrine Ephedrine
Pseudoephedrine HCL
Pseudoephedrine hydrochloride
Pseudoephedrinum
Pseudoephedrinum [INN-Latin]
Psi-ephedrin
Psi-ephedrine
Robidrine
SPBio_001365
Spectrum_000878
Spectrum2_001303
Spectrum3_001771
Spectrum4_001162
Spectrum5_000650
STOCK1N-42675
Sudafed
Sudafed Decongestant
Sudafed Decongestant 12 Hour
Sudafed Decongestant Extra Strength
threo Isomer OF ephedrine
trans-Ephedrine
Triaminic AM Decongestant Formula
Triaminic Infant Oral Decongestant Drops
UNII-7CUC9DDI9F
ψ-ephedrine
|
|
| 6 |
|
Ephedrine |
Approved |
Phase 1, Phase 2 |
|
299-42-3 |
9294
|
|
Synonyms:
( )-Pseudoephedrine
(-)-Ephedrine
(-)-Pseudoephedrine
(-)-psi-Ephedrine
(-)-threo-Ephedrine
(+)-Ephedrin
(+)-Ephedrine
(+-)-Ephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(1R,2R)-Ephedrine
(1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane
(1S,2R)-Ephedrine
(L)-EPHEDRINE
134910_ALDRICH
1-EPHEDRINE
1-Sedrin
287636_ALDRICH
287644_ALDRICH
299-42-3
304-87-0
30987-59-8
321-96-0
321-97-1
321-98-2
37577-31-4
38732-95-5
45261_FLUKA
4607-45-8
50906-05-3
50-98-6
53214-57-6
649031_ALDRICH
6912-63-6
7009-81-6
90-82-4
968-63-8
AC1L1JGK
AC1L1NUA
AC1L1RFA
AC1L1SR1
AC1L1T31
AC1L1Y3M
AC1O8JUO
AC1Q3XJE
AC1Q3XJM
AC1Q3XJN
AC1Q59F5
AC1Q7701
AC-20231
AC-20292
Acunaso
Acunaso (TN)
Afrinol
AI3-02761
AKOS000268842
Ambap299-42-3
AR-1A0126
AR-1I7143
Benylin Decongestant
Besan
BIDD:GT0817
Biophedrin
BRN 3197916
BRN 4231286
BSPBio_001946
BSPBio_001968
BSPBio_003261
C01575
C02765
C10H15NO
Cenafed
CHEBI:15407
CHEBI:51209
CHEMBL1590
CHEMBL211456
CHEMBL357080
CID11972440
CID5032
CID62946
CID6710657
CID7028
CID8650
CID9294
CID9457
CPD-9954
CPDD 0049
D00124
D08449
DB00852
DB01364
Decofed
d-Ephedrine
d-Isoephedrine
DivK1c_000181
DivK1c_000451
DivK1c_000461
d-Pseudoephedrine
d-psi-Ephedrine
Drixoral N.D.
Eciphin
Efedrin
Efidac/24
EINECS 202-017-0
EINECS 202-018-6
EINECS 206-080-5
EINECS 206-292-8
EINECS 206-293-3
Eltor 120
Ephedral
Ephedremal
Ephedrin
Ephedrine
--EPHEDRINE
Ephedrine (TN)
Ephedrine (USP)
Ephedrine [USAN:BAN]
Ephedrine erythro isomer
Ephedrine hydrochloride
Ephedrine l-form
Ephedrine renaudin
Ephedrine sulfate
Ephedrital
Ephedrol
Ephedrosan
Ephedrotal
Ephedsol
Ephendronal
Ephoxamin
erythro Isomer OF ephedrine
Fedrin
Genaphed
HSDB 3072
HSDB 3177
Hydrochloride, ephedrine
I01-3584
I01-8925
|
I01-8928
IDI1_000181
IDI1_000451
IDI1_000461
I-Sedrin
Isoephedrine
Jsp005664
KBio1_000181
KBio1_000451
KBio1_000461
KBio2_001358
KBio2_001500
KBio2_003926
KBio2_004068
KBio2_006494
KBio2_006636
KBio3_001188
KBio3_001446
KBio3_002762
KBioGR_001013
KBioGR_001763
KBioSS_001358
KBioSS_001500
Kratedyn
KST-1A9168
L(−)-ephedrine
L(-)-Ephedrine
L-(-)-Ephedrine
L-(+)-Ephedrine
L(+)-psi-Ephedrine
L000968
l-Ephedrine
L-Ephedrine
L-erythro-2-(methylamino)-1-Phenylpropan-1-ol
L-erythro-2-(Methylamino)-1-phenylpropan-1-ol
Lexofedrin
Lopac0_000501
Lopac-E-3250
l-Pseudoephedrine
LS-125921
LS-125922
LS-43083
LS-63961
LS-63962
LS-63963
LS-63964
Manadrin
Mandrin
Maxenal
MLS000069657
MolPort-001-684-474
MolPort-001-684-477
MolPort-001-684-478
MolPort-001-684-479
MolPort-001-769-085
Myfedrine
Nasol
NCGC00015408-01
NCGC00015408-02
NCGC00162174-01
NCGC00178180-01
NCGC00178889-01
NCI60_002955
NCI-C55652
Neodurasina
Neodurasina (TN)
NINDS_000181
NINDS_000451
NINDS_000461
NSC 165609
NSC 170951
NSC 8971
NSC165609
NSC170951
NSC8971
Oprea1_287330
PDSP1_000168
PDSP1_001106
PDSP1_001343
PDSP1_001345
PDSP1_001346
PDSP1_001347
PDSP2_000167
PDSP2_001090
PDSP2_001327
PDSP2_001329
PDSP2_001330
PDSP2_001331
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
PSEUDOEPHEDRINE
Pseudoephedrine (D)
Pseudoephedrinum
Psi-ephedrin
Psi-ephedrine
racephedrine
Renaudin brand OF ephedrine hydrochloride
Renaudin, ephedrine
Robidrine
Sal phedrine
Sal-phedrine
SalPhedrine
Sanedrine
SMR000059174
SPBio_000214
SPBio_001365
SPBio_001377
Spectrum_000878
Spectrum_001020
Spectrum2_000137
Spectrum2_001303
Spectrum2_001309
Spectrum3_000414
Spectrum3_000563
Spectrum3_001771
Spectrum4_000497
Spectrum4_001162
Spectrum5_000650
Spectrum5_000879
Spectrum5_001106
ST023802
STK367993
STOCK1N-42675
Sudafed
Sudafed Decongestant
Sulfate, ephedrine
trans-Ephedrine
UNII-03VRY66076
UNII-7CUC9DDI9F
UNII-GN83C131XS
Vencipon
Wendt brand OF ephedrine sulfate
WLN: QYR & Y1 & M1
WLN: QYR&Y1&M1
Zephrol
|
|
| 7 |
|
Vasoconstrictor Agents |
|
Phase 1, Phase 2 |
|
|
|
| 8 |
|
Adrenergic Agents |
|
Phase 1, Phase 2 |
|
|
|
| 9 |
|
Central Nervous System Stimulants |
|
Phase 1, Phase 2 |
|
|
|
| 10 |
|
Sympathomimetics |
|
Phase 1, Phase 2 |
|
|
|
| 11 |
|
Respiratory System Agents |
|
Phase 1, Phase 2 |
|
|
|
| 12 |
|
Anti-Asthmatic Agents |
|
Phase 1, Phase 2 |
|
|
|
| 13 |
|
Neurotransmitter Agents |
|
Phase 1, Phase 2 |
|
|
|
| 14 |
|
Peripheral Nervous System Agents |
|
Phase 1, Phase 2 |
|
|
|
| 15 |
|
Bronchodilator Agents |
|
Phase 1, Phase 2 |
|
|
|
| 16 |
|
Autonomic Agents |
|
Phase 1, Phase 2 |
|
|
|
| 17 |
|
Nasal Decongestants |
|
Phase 1, Phase 2 |
|
|
|
| 18 |
|
Adrenergic beta-Agonists |
|
Phase 1 |
|
|
|
| 19 |
|
Adrenergic Agonists |
|
Phase 1 |
|
|
|
| 20 |
|
Tocolytic Agents |
|
Phase 1 |
|
|
|
| 21 |
|
Adrenergic beta-2 Receptor Agonists |
|
Phase 1 |
|
|
|
| 22 |
|
Albuterol |
|
Phase 1 |
|
|
|
| 23 |
|
Nivolumab |
Approved |
|
|
946414-94-4 |
|
|
Synonyms:
|
Interventional clinical trials:
(show all 24)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) |
Completed |
NCT01377922
|
Phase 3 |
Amifampridine Phosphate;Placebo |
| 2 |
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) |
Completed |
NCT02970162
|
Phase 3 |
Amifampridine Phosphate;Placebo Oral Tablet |
| 3 |
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes |
Recruiting |
NCT02562066
|
Phase 3 |
amifampridine phosphate;Placebo |
| 4 |
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) |
Recruiting |
NCT03486873
|
Phase 3 |
Standard of Care (SOC) |
| 5 |
Ephedrine for the Treatment of Congenital Myasthenia |
Unknown status |
NCT00541216
|
Phase 1, Phase 2 |
Ephedrine |
| 6 |
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome |
Completed |
NCT01511978
|
Phase 2 |
Continuous 3,4-DAP;Taper 3,4-DAP to Placebo |
| 7 |
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes |
Completed |
NCT01203592
|
Phase 1 |
Albuterol |
| 8 |
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome |
Completed |
NCT00004832
|
Not Applicable |
3,4-diaminopyridine |
| 9 |
Pregnancy Outcomes in Congenital Myasthenie Syndrome |
Completed |
NCT01474980
|
|
|
| 10 |
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) |
Recruiting |
NCT00872950
|
Not Applicable |
3,4-DIAMINOPYRIDINE;3,4-Diaminopyridine |
| 11 |
Congenital Muscle Disease Study of Patient and Family Reported Medical Information |
Recruiting |
NCT01403402
|
|
|
| 12 |
National Registry for Egyptian Pediatric Neuromuscular Diseases |
Recruiting |
NCT02124616
|
|
|
| 13 |
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice |
Recruiting |
NCT02847728
|
|
|
| 14 |
Observational Study of Nivolumab in Patients in Germany With Squamous Cell Carcinoma of the Head and Neck Progressing on or After Platinum-Based Therapy |
Recruiting |
NCT03114163
|
|
|
| 15 |
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine |
Available |
NCT00994916
|
|
3,4 diaminopyridine |
| 16 |
Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome |
Available |
NCT03062631
|
|
3,4-Diaminopyridine |
| 17 |
Treatment of Lambert-Eaton Syndrome With 3,4 DAP |
Available |
NCT00704925
|
|
3, 4 DAP |
| 18 |
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM) |
Available |
NCT02012933
|
|
3,4-diaminopyridine |
| 19 |
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome |
Available |
NCT01825395
|
|
3, 4-Diaminopyridine |
| 20 |
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients |
Available |
NCT02189720
|
|
Amifampridine Phosphate |
| 21 |
Treatment Use of 3,4-Diaminopyridine |
Available |
NCT01765140
|
|
3,4-diaminopyridine;3,4-diaminopyridine |
| 22 |
Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) |
Enrolling by invitation |
NCT02090725
|
Not Applicable |
3-4 Diaminopyridine |
| 23 |
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome |
No longer available |
NCT01373333
|
|
3,4 DAP |
| 24 |
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP |
No longer available |
NCT01378546
|
|
3,4-diaminopyridine |
|
